Clinical Trials

Date: 2015-05-13

Type of information: Initiation of the trial

phase: 1

Announcement: initiation of the trial

Company: GSK (UK) Emergent BioSolutions (USA - MD) University of Oxford (UK)

Product: modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ)

Action mechanism: vaccine

Disease: Ebola fever

Therapeutic area: Infectious diseases

Country: UK

Trial details:

Latest news:

• On May 13, 2015, a new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) as a prime-boost to GSK\'s Chimp Adenovirus type 3 (ChAd3) Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom\'s Medicines and Healthcare Products Regulatory Agency (MHRA). The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development. Dr. Moncef Slaoui, Chairman of Vaccines, GSK, said: "We believe there is benefit in exploring different approaches such as a prime-boost strategy as we continue to develop our ChAd3 Ebola candidate vaccine. This ChAd3 Ebola candidate vaccine has shown encouraging immune responses and an acceptable safety and reactogenicity profile in ongoing phase 1 trials to date. Together, these different trials will provide important information about the vaccine and its potential to help combat this or future Ebola outbreaks.\"